Published by Josh White on 4th September 2017
(ShareCast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals announced on Monday that the FDA had proposed that the company could proceed directly to Biologics License Application (BLA) submission, pending positive results from the two ongoing Phase III trials with the company's wholly-owned product, 'Traumakine', for the treatment of acute respiratory distress syndrome (ARDS).